Galectin Therapeutics reported $227K in Interest Expense on Debt for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Interest Expense On Debt Change
Bristol Myers Squibb BMY:US $ 313M 13M
Galectin Therapeutics GALT:US $ 227K 45K
Gilead Sciences GILD:US $ 242M 4M
Intercept Pharmaceuticals ICPT:US $ 6.67M 0M
Regulus Therapeutics RGLS:US $ 0.16M 0.06M
YTE INCY:US $ 0.68M 0M